Latest Breaking News On - Alpha bronze - Page 1 : vimarsana.com

NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes

NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAlex zwyerRonald hafnerGeorge apostolCindy rizzoPascal nigenExchange commissionAlpha bronzeLaidlaw company united kingdom ltdEuropean medicines agencyPharmaceutics ltdWall streetChief medical officerUnited kingdomSecurities actOrphan disease designation

NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes

NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

United statesAlex zwyerRonald hafnerGeorge apostolCindy rizzoPascal nigenExchange commissionAlpha bronzeLaidlaw company united kingdom ltdEuropean medicines agencyPharmaceutics ltdChief medical officerUnited kingdomSecurities actOrphan disease designationMazindol controlled release

NLS Pharmaceutics AG: NLS Pharmaceutics Announces $4 Million Private Placement and Conversion of Existing Short-Term Notes

ZURICH, SWITZERLAND / ACCESSWIRE / October 3, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and

United statesAlex zwyerRonald hafnerGeorge apostolCindy rizzoPascal nigenExchange commissionAlpha bronzeLaidlaw company united kingdom ltdEuropean medicines agencyPharmaceutics ltdChief medical officerUnited kingdomSecurities actOrphan disease designationMazindol controlled release

NLS Pharmaceutics AG: NLS Pharmaceutics Announces Positive Top-Line Results from its Phase 2a Clinical Trial of Once-Daily Quilience for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Statistically significant results with Quilience® (Mazindol ER) achieving a 7.1 point mean reduction in ESS from baseline compared to a 3.2 point reduction for placebo, p=0.0081Fast onset of action from

United statesAlex zwyerBruce corserAnne marie morseGeorge apostolPascal nigenCindy rizzoNovant healthDrug administrationGeisinger medical centerPharmaceutics ltdExchange commissionAlpha bronzeManagement instituteEuropean medicines agencyEpworth sleepiness scale

NLS Pharmaceutics AG: NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience Top-Line Phase 2a Narcolepsy Results

ZURICH, SWITZERLAND / ACCESSWIRE / September 19, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP), (Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery

United statesAlex zwyerBruce corserAnne marie morseGeorge apostolCindy rizzoPascal nigenNovant healthGeisinger medical centerPharmaceutics ltdExchange commissionAlpha bronzeManagement instituteEuropean medicines agencyVirtual key opinion leaderChief medical officer